A cellular model of inflammation for identifying TNF-α synthesis inhibitors

Journal of Neuroscience Methods

Volumn 183, Issue 2, 2009, Pages 182-187

  Tweedie, David ^a   Luo, Weiming ^a   Short, Ryan G ^a   Brossi, Arnold ^b   Holloway, Harold W ^a   Li, Yazhou ^a   Yu, Qian sheng ^a   Greig, Nigel H ^a  

^a Drug Design and Development Section   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Alzheimer's disease; Lenalidomide; Lipopolysaccharide (LPS); Neurodegeneration; Neuroinflammation; RAW 264.7; Thalidomide; TNF

Indexed keywords

3,2,6' TRITHIOTHALIDOMIDE; 3,6 DITHIOTHALIDOMIDE; CYTOKINE; DITHIOGLUTARIMIDE; DITHIOPTHALIMIDE; LIPOPOLYSACCHARIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THIOTHALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DRUG PENETRATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOPHILICITY; MACROPHAGE; MALE; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; PRIORITY JOURNAL; RAT; RODENT; STROKE;

ANIMALS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; RATS; RATS, INBRED F344; STATISTICS, NONPARAMETRIC; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69949098953     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2009.06.034     Document Type: Article

References (20)

1. Bosshart H., and Heinzelmann M. Targeting bacterial endotoxin: two sides of a coin. Ann NY Acad Sci 1096 (2007) 1-17
2. Falco P., Cavallo F., Larocca A., Liberati A.M., Musto P., Boccadoro M., et al. Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8 (2008) 865-874
3. Jones J.O., and Diamond M.I. Design and implementation of cell-based assays to model human disease. ACS Chem Biol 2 (2007) 718-724
4. Lahiri D.K., Farlow M.R., and Sambamurti K. The secretion of amyloid-beta peptides is inhibited in tacrine-treated human neuroblastoma cells. Mol Brain Res 62 (1998) 131-140
5. Maccioni R.B., Rojo L.E., Fernández J.A., and Kuljis R.O. The role of neuroimmunomodulation in Alzheimer's disease. Ann NY Acad Sci 1153 (2009) 240-246
6. McClain C.J., Hill D.B., Song Z., Chawla R., Watson W.H., Chen T., et al. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol 27 (2002) 185-192
7. Melchert M., and List A. The thalidomide saga. Int J Biochem Cell Biol 39 (2007) 1489-1499
8. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
9. Nakao N., Kurokawa T., Nonami T., Tumurkhuu G., Koide N., and Yokochi T. Hydrogen peroxide induces the production of tumor necrosis factor-alpha in RAW 264.7 macrophage cells via activation of p38 and stress-activated protein kinase. Innate Immun 14 (2008) 190-196
10. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., and San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9 (2008) 1157-1165
11. Pillemer S.R., Leakan R.A., Sankar V., Manny J., Baum B.J., Smith J., et al. Prominent adverse effects of thalidomide in primary Sjögren's syndrome. Arthritis Rheum 51 (2004) 505-506
12. Rogers J.T., and Lahiri D.K. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5 (2004) 535-551
13. Rogers J., Mastroeni D., Leonard B., Joyce J., and Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int Rev Neurobiol. 82 (2007) 235-246
14. Shannon E.J., and Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 18 (1996) 59-72
15. Schinazi R.F., Ilan E., Black P.L., Yao X., and Dagan S. Cell-based and animal models for hepatitis B and C viruses. Antivir Chem Chemother 10 (1999) 99-114
16. Streit W.J., Conde J.R., Fendrick S.E., Flanary B.E., and Mariani C.L. Role of microglia in the central nervous system's immune response. Neurol Res 27 7 (2005) 685-691
17. Tobinick E. Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res 4 (2007) 550-552
18. Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med 10 (2008) 135
19. Tweedie D., Sambamurti K., and Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 4 (2007) 378-385
20. Zhu X., Giordano T., Yu Q.S., Holloway H.W., Perry T.A., Lahiri D.K., et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem 46 (2003) 5222-5229